Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2026 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) updated its FY 2026 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 7.750-8.250 for the period, compared to the consensus estimate of 8.010. The company issued revenue guidance of $1.7 billion-$1.8 billion, compared to the consensus revenue estimate of $1.8 billion.

Analyst Upgrades and Downgrades

Several analysts have weighed in on HALO shares. Benchmark lifted their target price on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. HC Wainwright increased their price objective on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Wells Fargo & Company boosted their target price on Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a report on Thursday, February 19th. Finally, Wall Street Zen lowered Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Saturday, February 21st. Six research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $79.11.

Halozyme Therapeutics Trading Up 3.6%

NASDAQ:HALO opened at $66.41 on Tuesday. The stock has a fifty day simple moving average of $65.68 and a 200 day simple moving average of $68.57. The firm has a market capitalization of $7.87 billion, a price-to-earnings ratio of 26.67, a price-to-earnings-growth ratio of 0.26 and a beta of 0.89. Halozyme Therapeutics has a 1-year low of $47.50 and a 1-year high of $82.22. The company has a quick ratio of 3.66, a current ratio of 4.66 and a debt-to-equity ratio of 43.89.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. The company had revenue of $376.71 million during the quarter, compared to analysts’ expectations of $358.60 million. During the same period last year, the company posted $1.11 earnings per share. The business’s revenue for the quarter was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Sell-side analysts forecast that Halozyme Therapeutics will post 7.68 earnings per share for the current year.

Insider Activity

In other news, COO Cortney Caudill sold 20,000 shares of the business’s stock in a transaction on Monday, March 9th. The shares were sold at an average price of $67.80, for a total transaction of $1,356,000.00. Following the transaction, the chief operating officer directly owned 14,366 shares in the company, valued at $974,014.80. The trade was a 58.20% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $64.24, for a total value of $1,284,800.00. Following the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $49,322,187.20. The trade was a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 90,482 shares of company stock worth $6,073,942 in the last 90 days. Company insiders own 2.50% of the company’s stock.

Key Headlines Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Halozyme beat Q1 estimates, reporting EPS of $1.60 versus $1.54 expected and revenue of $376.7 million versus $358.6 million expected, with sales up 42.2% year over year. HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
• Positive Sentiment: The company also announced a new $1 billion share repurchase program and said it expects to buy back at least $400 million in 2026, signaling confidence in cash generation and shareholder returns. HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
• Neutral Sentiment: Management reiterated full-year 2026 guidance for revenue, royalty revenue, adjusted EBITDA, and non-GAAP EPS, which suggests steady expectations but does not appear to be a major upside surprise versus consensus. HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
• Neutral Sentiment: Recent analyst coverage remains constructive, including Buy ratings and price targets as high as $95, which may help sentiment but is secondary to the earnings release. H.C. Wainwright Bullish on Halozyme Therapeutics, Inc. (HALO) Commercial Revenue Outlook
• Negative Sentiment: One earnings-focused recap noted EPS of $1.22 on a third-party basis, below estimates, highlighting that some investors may focus on margin or accounting details despite the strong top-line beat. Halozyme Therapeutics (HALO) Releases Q1 2026 Earnings: Revenue Beats Estimates but EPS Miss

Institutional Investors Weigh In On Halozyme Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Larson Financial Group LLC lifted its position in shares of Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 343 shares during the last quarter. Wexford Capital LP acquired a new stake in Halozyme Therapeutics in the 3rd quarter worth approximately $70,000. Employees Retirement System of Texas grew its holdings in Halozyme Therapeutics by 64.6% during the third quarter. Employees Retirement System of Texas now owns 1,088 shares of the biopharmaceutical company’s stock valued at $80,000 after purchasing an additional 427 shares during the last quarter. UMB Bank n.a. raised its position in shares of Halozyme Therapeutics by 18.2% in the fourth quarter. UMB Bank n.a. now owns 1,296 shares of the biopharmaceutical company’s stock valued at $87,000 after purchasing an additional 200 shares during the period. Finally, Smartleaf Asset Management LLC raised its position in shares of Halozyme Therapeutics by 21.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the biopharmaceutical company’s stock valued at $95,000 after purchasing an additional 251 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.